Burning Rock Biotech said Wednesday that its second quarter revenues were up about 3 percent year over year.

BioMérieux on Wednesday reported sales growth of approximately 5 percent for the first half of 2022 compared to the first half of 2021.

Merck, known as MSD outside the United States and Canada, today announced that the U.S. FDA has granted Fast Track designation for Merck’s investigational anticoagulant therapy MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease.

Lucira Health announced on Thursday that it has received authorization under an interim order from Health Canada to market the Lucira COVID-19 & Flu Test for emergency use.

Roche announced on Thursday that it has received approval from the US Food and Drug Administration for a label expansion of its Ventana MMR RxDx Panel to determine which solid tumor patients could benefit from treatment with Merck's Keytruda (pembrolizumab).

Hyris said on Friday that it has received CE-IVD marking for its T-Cell Test for tracking and monitoring T-cell immunity to SARS-CoV-2.

The rebound from COVID-19 created a huge tailwind for the world’s largest companies by revenue. Aggregate sales for the Fortune Global 500 hit $37.8 trillion, an increase of 19%—the highest annual growth rate in the list’s history.

Following extraordinary demand for rapid COVID-19 antigen testing in 2021, Siemens Healthineers reported on Wednesday that the company's fiscal third quarter COVID-19 testing revenue declined sharply

Rising demand for core diagnostics offset better-than-feared declines in COVID-19 test sales, shedding light on the companies’ post-pandemic futures.

Meridian Bioscience said on Friday that the Emergency Use Authorization for its Revogene SARS-CoV-2 molecular test has been reissued by the US Food and Drug Administration.